| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BTLA |
| Uniprot No | Q7Z6A9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-150aa |
| 氨基酸序列 | KESCDVQLYI KRQSEHSILA GDPFELECPV YCANRPHVT WCKLNGTTCV KLEDRQTSWK EEKNISFFIL FEPVLPNDN GSYRCSANFQ SNLIESHSTT LYVTDVKSAS RPSKDEMAS |
| 预测分子量 | 42 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BTLA重组蛋白的3篇参考文献概览：
---
1. **文献名称**: *BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1*
**作者**: Watanabe N, et al.
**摘要**: 该研究首次克隆并鉴定了BTLA蛋白，证明其在T/B细胞中抑制活化信号。通过重组BTLA蛋白与配体HVEM的相互作用实验，揭示了其作为免疫检查点分子的功能。
2. **文献名称**: *B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator*
**作者**: Sedy JR, et al.
**摘要**: 研究利用重组BTLA和HVEM蛋白证实两者结合可抑制T细胞增殖及细胞因子分泌，首次阐明HVEM是BTLA的功能性配体，并证明该通路在免疫调控中的关键作用。
3. **文献名称**: *Crystal structure of the BTLA-HVEM complex reveals the molecular basis of receptor-ligand cross-talk*
**作者**: Compaan DM, et al.
**摘要**: 通过重组BTLA和HVEM蛋白的共结晶分析，解析了二者结合的分子机制，发现BTLA的CRD1结构域与HVEM相互作用，为设计靶向该通路的药物提供结构基础。
---
以上研究均涉及重组BTLA蛋白的应用，涵盖功能验证、配体互作及结构解析等领域。
**Background of BTLA Recombinant Protein**
B and T lymphocyte attenuator (BTLA), a member of the immunoglobulin superfamily, is an immune checkpoint receptor expressed on lymphocytes, dendritic cells, and macrophages. It shares structural and functional similarities with other inhibitory receptors like CTLA-4 and PD-1. BTLA interacts primarily with herpesvirus entry mediator (HVEM), a tumor necrosis factor receptor family protein, to deliver co-inhibitory signals that modulate immune activation and tolerance. This interaction plays a critical role in dampening excessive immune responses, maintaining homeostasis, and preventing autoimmunity. Dysregulation of BTLA signaling has been implicated in cancer, chronic infections, and autoimmune disorders, making it a target for therapeutic interventions.
BTLA recombinant protein is engineered to mimic the extracellular domain of BTLA, often produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. The protein is typically purified via affinity tags (e.g., His-tag) and validated for binding activity with HVEM. Its applications include *in vitro* studies to elucidate BTLA-HVEM interaction mechanisms, high-throughput screening for inhibitors or agonists, and development of biologics (e.g., soluble BTLA decoys or monoclonal antibodies) to either block or enhance BTLA-mediated signaling.
Research leveraging BTLA recombinant protein has advanced understanding of immune evasion in tumors, where upregulated BTLA may suppress antitumor immunity. Conversely, BTLA agonists are explored to treat autoimmune diseases by restoring immune tolerance. As a tool, this recombinant protein bridges basic immunology and translational drug discovery, highlighting its dual significance in mechanistic research and therapeutic innovation.
×
